
Alta Partners is a leading healthcare and life sciences venture capital firm based in San Francisco, founded in 1996. The firm invests in early-stage curative therapeutics and technology-enabled healthcare services through its family of NextGen funds.
Average disclosed round size is $52.4M (across 57 rounds with reported amounts).
Portfolio
51
Fund Size
$275M
Top Stage
Series B
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
62 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Unknown | — | Nov 2024 | |
| Series A | $65M | May 2024 | |
| Series D | $126M | May 2024 | |
| Series C | $95.5M | Jan 2024 | |
| Series D | $126M | Jan 2024 | |
| Series B | $85M | Jan 2023 | |
| Series B | $85M | Jan 2023 | |
| EEverside Health | Growth | $164M | Jul 2022 |
| Unknown | $70M | Jun 2022 | |
| Series B | $47M | Jan 2022 | |
| Series C | — | Jan 2022 | |
| Series B | — | Jan 2022 | |
| Series B | $106M | Mar 2021 | |
| Unknown | $26M | Jan 2021 | |
| Series C | $135.8M | Jun 2020 | |
| Series A | $50M | Jan 2020 | |
| Growth | $33M | May 2019 | |
| TTechnisys | Series C | $50M | Apr 2019 |
| AAlly Therapeutics | Seed | $10M | Jan 2019 |
| Growth | $165M | Aug 2018 | |
| EEvolve Biosystems | Series C | $40M | Jun 2018 |
| CCurasen | Series A | $54.5M | Jan 2018 |
| Seed | $1.4M | Jul 2016 | |
| Series A | $8M | Dec 2015 | |
| Series A | $5.6M | Nov 2014 |
Page 1 of 3
Top Co-Investors
New Enterprise Associates6 shared
General Catalyst5 shared
Longwood Fund5 shared
Amgen Ventures5 shared
RiverVest Venture Partners5 shared
Canaan Partners4 shared
RA Capital Management4 shared
Pivotal Life Sciences4 shared
Polaris Partners4 shared
Pappas Capital4 shared
Oak HC/FT3 shared
Endeavor3 shared
Domain Associates3 shared
Frazier Healthcare Partners3 shared
Atlas Venture3 shared
Venrock3 shared
OrbiMed3 shared
Geodesic Capital3 shared
Leaps by Bayer3 shared
Human Ventures3 shared
Last updated: 7 September 2026